Shire plc Director and Senior Management Changes

Shire plc Director and Senior Management Changes

Shire plc Director and Senior Management Changes

August 21,  2017  -  Shire  plc  (LSE: SHP,  NASDAQ:  SHPG)  ("Shire"  or  the 
"Company"), announces changes to its Executive Committee, as it progresses its
strategy to sharpen its focus as a leader in rare diseases. 

Jeff Poulton, Chief Financial Officer, will be leaving Shire at the end of the
year to serve as CFO  at Indigo Ag, Inc., a  start-up company based in  Boston 
that uses the plant microbiome to improve the productivity and  sustainability 
of agriculture. The Board  will commence a formal  search for a successor  and 
Jeff will continue  to serve in  his current role  as this search  progresses. 
During this transition period, Jeff will remain on the Executive Committee and
on the Board of Directors of Shire plc. Jeff will also continue to support the
Company's on-going strategic review of its business.

Dr. Flemming Ornskov,  MD, MPH,  Chief Executive  Officer, said:  "It is  with 
regret that we announce Jeff's upcoming departure. Having held numerous  roles 
within the  Company,  Jeff  has demonstrated  steadfast  commitment  to  Shire 
through  a  very  intense  period   of  activity  and  has  made   significant 
contributions to  our  organization. Jeff  will  continue to  lead  the  Shire 
Finance team through the Q3 reporting period  and to the end of the year,  and 
will play an active role  in the search for his  successor.  On behalf of  all 
Shire employees, we are grateful to Jeff for his dedication and leadership and
wish him the very best in his future endeavours."        

Jeff Poulton, Chief Financial Officer, said: "It has been a privilege to  work 
for Shire and to have played a part in the exceptional growth story of such an
inspirational company.  It has  been a  difficult decision,  but in  departing 
Shire, I wanted  to join a  smaller organization where  I can play  a role  in 
building a new  company.  As Shire  finalizes the integration  of Baxalta  and 
focusses on paying  down debt, this  also presents  a perfect time  for me  to 
begin this transition.   I know I  leave Shire well  positioned to pursue  its 
strategy and deliver  value for  shareholders, supported by  a strong  Finance 
team."  

Susan Kilsby,  Chairman  of  the Board,  said:  "On  behalf of  the  Board  of 
Directors, I want to thank Jeff for his long tenure and unwavering  dedication 
to Shire  and our  patients. While  we will  miss Jeff's  positive spirit  and 
professionalism, we  understand his  decision to  start a  new career.  During 
Jeff's time  at Shire  he has  travelled the  globe, transformed  the  Finance 
department, and led the continued  successful integration of Baxalta and  many 
other acquisitions. We fully appreciate his contributions that have helped  to 
make Shire a great organization."

This notification is to satisfy the Company's obligations under LR 9.6.11R  of 
the UK Listing Rules.

The Company also announces that Joanne Cordeiro has been appointed Chief Human
Resources  Officer  and  a  member  of  the  Executive  Committee,   effective 
immediately. Joanne takes over the role held by Ginger Gregory.  Joanne joined
Shire in March 2011 and  has been serving as  Interim Head of Human  Resources 
since March  2017.  Before  joining  Shire, Joanne  served  in  various  Human 
Resources management and  executive search  roles at  Teradyne Inc.,  Covansys 
Corporation (now a DXC Technology Company), Avid Technology, Inc., and  Sybase 
Inc. (now an SAP company).

In reference to Joanne's appointment, Dr. Ornskov said: "I have worked closely
with Joanne over the past several years as we have transformed Shire into  the 
global leader in the treatment  of rare diseases. Joanne's dedication,  skill, 
and expertise have been an  invaluable resource in the successful  integration 
of Baxalta into the Shire  business.  She is a  trusted partner to the  entire 
management team  and  a  passionate  supporter  of  our  in-house  talent  and 
leadership development programs, which are crucial to our business."

Joanne Cordeiro,  Chief Human  Resources Officer,  said: "It  is an  honor  to 
accept this appointment  and I  look forward  to the  opportunity to  continue 
building on the expertise  and passion of my  colleagues at Shire,  attracting 
top talent to  our organization, and  working with the  rest of the  Executive 
Committee, all of whom are dedicated to improving the lives of the patients we
serve."

For further information please contact:

Investor Relations                        
Ian Karp           ikarp@shire.com       +1 781 482 9018
Robert Coates      rcoates@shire.com     +44 1256 894874
Media                                     
Lisa Adler         lisa.adler@shire.com  +1 617 588 8607
Debbi Ford         debbi.ford@shire.com  +1 617 949 9083

For information regarding Indigo Ag, Inc., please contact:

                lashbrook@indigoag.com + 1 617 909-9390
Lauren Ashbrook
                                        

NOTES TO EDITORS

Stephen Williams, Deputy Company Secretary, is responsible for arranging the
release of this announcement.

Inside Information

This announcement contains inside information.

Remuneration

Jeff Poulton will continue to be paid in line with his current remuneration
arrangements until his date of departure. Details of the remuneration
arrangements relating to Mr. Poulton's departure will be disclosed in due
course. 

About Shire

Shire is the leading  global biotechnology company  focused on serving  people 
with rare diseases. We strive to develop best-in-class products, many of which
are available  in  more than  100  countries, across  core  therapeutic  areas 
including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage
Disorders, Gastrointestinal  / Internal  Medicine /  Endocrine and  Hereditary 
Angioedema; and a growing franchise in Oncology.

Our employees come to  work every day  with a shared  mission: to develop  and 
deliver breakthrough therapies for the hundreds  of millions of people in  the 
world affected by rare diseases and  other high-need conditions, and who  lack 
effective therapies to live their lives to the fullest.

www.shire.com
Press spacebar to pause and continue. Press esc to stop.